Loss of Fas Expression and Function Is Coupled With Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Molecular Cancer Research - United States
doi 10.1158/1541-7786.mcr-18-0455
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Systemic Immunotherapy of Superficial Mouse Bladder Cancer With Avelumab (MSB0010718C), an Anti-Pd-L1 Immune Checkpoint Inhibitor

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy

Mayo Clinic Proceedings
Medicine
2019English

Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer

Arthritis and Rheumatology
RheumatologyAllergyImmunology
2017English

Immunotherapy and Colon Cancer

Integrative Cancer Science and Therapeutics
2016English

TNFR2 and Regulatory T Cells: Potential Immune Checkpoint Target in Cancer Immunotherapy

2019English

Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy

Case Reports in Oncological Medicine
Oncology
2017English

Immune Response in Melanoma: A Basis to Understand the Role of Immunotherapy With Immune Checkpoint Inhibitors

Revista da Sociedade Portuguesa de Dermatologia e Venereologia
2018English

Local Angiotensin II Contributes to Tumor Resistance to Checkpoint Immunotherapy

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy